New insulin strength could simplify diabetes care

NCT ID NCT03903016

Completed Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two versions of insulin lispro—one standard strength and one double-strength—to see if they work the same in the body. About 90 adults with type 1 diabetes will receive a single dose of each in random order. The goal is to check if the stronger formula is bioequivalent, meaning it could offer a convenient alternative without changing how the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: insulin lispro
What this could lead to: If successful, this could confirm that a more concentrated insulin lispro is as effective as the standard version, offering more dosing options for people with type 1 diabetes.
What could go wrong: This is an early-phase study focused on bioequivalence, not on long-term outcomes or safety. It may not translate to real-world benefits or detect rare side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Investigational Site Number 2760001

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.